OOIR: Observatory of International Research

Papers

(The H4-Index of Lung Cancer is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Risk-Based lung cancer screening: A systematic review	128
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe	100
Mechanisms of osimertinib resistance and emerging treatment options	87
Covid-19 and lung cancer: A greater fatality rate?	86
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world dat	85
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer	81
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors	72
Lung cancer prediction by Deep Learning to identify benign lung nodules	71
Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype	68
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer	67
Vaping and lung cancer – A review of current data and recommendations	62
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study	62
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients	62
Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer	60
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO	59
Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkp	53
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC	53
Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis	51
Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy	51
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy	49
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)	48
Temporal trends of the lung cancer mortality attributable to smoking from 1990 to 2017: A global, regional and national analysis	43
KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma	43
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)	42
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience	42

Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial	41
A cross-modal 3D deep learning for accurate lymph node metastasis prediction in clinical stage T1 lung adenocarcinoma	41
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer	41
Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma	41
Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study	40
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure	40
Cytology for PD-L1 testing: A systematic review	39
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer	38
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (Che	36
Baseline Results of the West London lung cancer screening pilot study – Impact of mobile scanners and dual risk model utilisation	35
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)	35